



**Simon Jackson, PhD**  
Executive Director, Cardiometabolic  
Disorders

Simon received his Ph.D. in Biochemistry from the University of Manchester, UK, in 1986, completed postdoctoral training at UCLA and served as Adjunct Assistant Professor at the same institution from 1996 to 2000. Simon joined the Tularik Biology group in South San Francisco in 2000 working on small molecule inhibitors of an obesity target. He subsequently became part of the Metabolic Disorders group of Amgen Inc in 2004 following the Tularik acquisition. At Amgen Simon has worked on the biology of PCSK9 and the antibody program for inhibiting PCSK9, leading to the launch of Repatha for the treatment of hypercholesterolemia in high risk patients with atherosclerotic cardiovascular disease. Currently, Simon is the lead for the Atherosclerosis and Vascular Biology group in the Cardiometabolic Disorders Therapeutic Area.